Esma Yildiz

The discovery of clustered regularly ınterspaced short palindromic repeats (CRISPR)–CRISPR-associated protein (Cas) systems as potent molecular instruments has transformed biosensing for the detection of viruses. These programmable nucleases, originally derived from bacterial immune mechanisms, offer high specificity, sensitivity and adaptability, making them ideal for diagnosing a wide range of viral infections. CRISPR-based diagnostics, including DNA endonuclease-targeted CRISPR trans reporter (DETECTR) and specific high-sensitivity enzymatic reporter unlocking (SHERLOCK), have been developed for rapid, cost-effective and field-deployable detection of both DNA and RNA viruses. This chapter provides a comprehensive overview of CRISPR–Cas biosensing technologies, categorizing detection methods for viral families such as Coronaviridae, Flaviviridae, Retroviridae and others. It explores key detection platforms, including fluorescence, electrochemical and colorimetric biosensors, highlighting their integration with isothermal amplification techniques and nanomaterials to enhance detection performance. Additionally, the chapter discusses recent advancements, challenges in clinical translation and potential future directions, including regulatory considerations and the integration of CRISPR with artificial intelligence and microfluidics. These innovations position CRISPR–Cas biosensors as transformative tools for molecular diagnostics, offering unprecedented speed and precision in viral detection, with implications for outbreak management, global health security and personalized medicine.

COVID-19, caused by SARS-CoV-2, has created unprecedented global health challenges, necessitating rapid and reliable diagnostic strategies. The spike (S) protein, particularly its S1 subunit, plays a critical role in viral entry, making it a prime biomarker for early detection. In this study, we present a disposable, low-cost, and portable electrochemical biosensor employing specifically optimized aptamers (Optimers) for SARS-CoV-2 S1 recognition. The sensing approach is based on aptamer–protein complex formation in solution, followed by immobilization onto pencil graphite electrodes (PGEs). The key parameters, including aptamer concentration, interaction time, redox probe concentration, and immobilization time, were systematically optimized by performing electrochemical measurement in redox probe solution containing ferri/ferrocyanide using differential pulse voltammetry (DPV) technique.Under optimized conditions, the biosensor achieved an ultralow detection limit of 18.80 ag/mL with a wide linear range (10⁻¹–10⁴ fg/mL) in buffer. Importantly, the sensor exhibited excellent selectivity against hemagglutinin antigen and MERS-CoV-S1 protein, while maintaining high performance in artificial saliva with a detection limit of 14.42 ag/mL. Furthermore, its integration with a smartphone-connected portable potentiostat underscores strong potential for point-of-care use. To our knowledge, this is the first voltammetric biosensor utilizing optimized aptamers (Optimers) specific to SARS-CoV-2 S1 on disposable PGEs, providing a robust and field-deployable platform for early COVID-19 diagnostics.

The main goal of our study is to demonstrate the applicability of the PPy-cryogel-modified electrodes for electrochemical detection of DNA. First, a polysaccharide-based cryogel was synthesized. This cryogel was then used as a template for chemical polypyrrole synthesis. This prepared polysaccharide-based conductive cryogel was used for electrochemical biosensing on DNA. Carrageenan (CG) and sodium alginate (SA) polysaccharides, which stand out as biocompatible materials, were used in cryogel synthesis. Electron transfer was accelerated by polypyrrole (PPy) synthesized in cryogel networks. A 2B pencil graphite electrode with a diameter of 2.00 mm was used as a working electrode. The prepared polysaccharide solution was dropped onto a working electrode as a support material to improve the immobilization capacity of biomolecules and frozen to complete the cryogelation step. PPy synthesis was performed on the electrodes whose cryogelation process was completed. In addition, the structures of cryogels synthesized on the electrode surface were characterized by thermogravimetric analysis (TGA), Fourier transform infrared spectroscopy (FTIR), and scanning electron microscopy (SEM). Surface characterization of the modified electrodes was performed by energy-dispersive X-ray spectroscopy (EDX) analysis. Electrochemical determination of fish sperm DNA (fsDNA) was performed using a PPy-cryogel-modified electrode. The use of a porous 3D cryogel intermediate material enhanced the signal by providing a large surface area for the synthesis of PPy and increasing the biomolecule immobilization capacity. The detection limit was 0.98 µg mL⁻¹ in the fsDNA concentration range 2.5–20 µg mL⁻¹. The sensitivity of the DNA biosensor was estimated to 14.8 µA mM⁻¹ cm⁻². The stability of the biosensor under certain storage conditions was examined and observed to remain 66.95% up to 45 days. Graphical Abstract

The interaction of drugs with DNA is important for the discovery of novel drug molecules and for understanding the therapeutic effects of drugs as well as the monitoring of side effects. For this reason, many studies have been carried out to investigate the interactions of drugs with nucleic acids. In recent years, a large number of studies have been performed to electrochemically detect drug-DNA interactions. The fast, sensitive, and accurate results of electrochemical techniques have resulted in a leading role for their implementation in this field. By means of electrochemical techniques, it is possible not only to demonstrate drug-DNA interactions but also to quantitatively analyze drugs. In this context, electrochemical biosensors for drug-DNA interactions have been examined under different headings including anticancer, antiviral, antibiotic, and central nervous system drugs as well as DNA-targeted drugs. An overview of the studies related to electrochemical DNA biosensors developed for the detection of drug-DNA interactions that were reported in the last two decades in the literature is presented herein along with their applications and they are discussed together with their future perspectives.

After the COVID-19 pandemic started all over the world, great importance was placed on the development of sensitive and selective bioanalytical assays for the rapid detection of the highly pathogenic SARS-CoV-2 virus causing COVID-19 disease. In this present work, an impedimetric immunosensor was developed and applied for rapid, reliable, sensitive and selective detection of the SARS-CoV-2 S1 protein. To detect the SARS-CoV-2 virus, targeting of the spike S1 protein was achieved herein by using S1 protein-specific capture antibody (Cab-S1) immobilized screen-printed electrode (SPE) in combination with the electrochemical impedance spectroscopy (EIS) technique. With the impedimetric immunosensor, the detection limit for S1 protein in buffer medium was found to be 0.23 ng/mL (equal to 23.92 amol in 8 µL sample) in the linear concentration range of S1 protein from 0.5 to 10 ng/mL. In the artificial saliva medium, it was found to be 0.09 ng/mL (equals to 9.36 amol in 8 µL sample) in the linear concentration range of S1 protein between 0.1 and 1 ng/mL. The selectivity of the impedimetric immunosensor toward S1 protein was tested against influenza hemagglutinin antigen (HA) in the buffer medium as well as in artificial saliva.